Trial site
Clinical Best Solutions Sp. z o.o. S.K.
Warsaw, 02-793, PolandEU-13 widening countryNot linked to an institution yet
- 12running trials
- 14closed trials
The trials here
What the 26 trials at this site are about, from their registry records.
- Phase
- Phase 320 trials
- Phase 26 trials
- Status
- Completed14 trials
- Active, not recruiting7 trials
- Recruiting5 trials
- Lead sponsor
- Alumis Inc2 trials
- Amgen Inc.2 trials
- Ionis Pharmaceuticals, Inc.2 trials
- MoonLake Immunotherapeutics AG2 trials
- Spyre Therapeutics, Inc.2 trials
- and 15 more
Running trials
Enrolling by invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294· Phase 2· Spyre Therapeutics, Inc.· Source
Recruiting
Confirmatory Clinical Study in Active Ulcerative Colitis
NCT07296315· Phase 2· MRM Health NV· Source
Active, not recruiting
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa
2025-520564-17-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00· Phase 3· Amgen Inc.· Source
Active, not recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.
2024-515672-12-00· Phase 3· Sun Pharmaceutical Industries Limited· Source
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395· Phase 2· Spyre Therapeutics, Inc.· Source
Active, not recruiting
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· Phase 3· Alumis Inc· Source
Recruiting
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis
2023-504724-25-00· Phase 3· Kartos Therapeutics Inc.· Source
Active, not recruiting
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076· Phase 3· Takeda· Source
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200· Phase 3· Anthos Therapeutics, Inc.· Source
Active, not recruiting
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
NCT05681351· Phase 3· Ionis Pharmaceuticals, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Active, not recruiting
A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis
NCT06630559· Phase 3· Celltrion· Source
Terminated
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT06685835· Phase 2· Insmed Incorporated· Source
Completed
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06602219· Phase 2· DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company· Source
Completed
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa
2024-511360-87-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Completed
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
NCT06588738· Phase 3· Alumis Inc· Source
Completed
A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the Treatment of Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse
2024-516672-16-00· Phase 3· Ab Science· Source
Completed
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864· Phase 3· Boehringer Ingelheim· Source
Completed
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
NCT06088043· Phase 3· Takeda· Source
Completed
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon)
2022-501538-44-00· Phase 3· Amgen Inc.· Source
Completed
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
NCT05610280· Phase 3· Ionis Pharmaceuticals, Inc.· Source
Completed
The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
NCT05162586· Phase 2· EMD Serono Research & Development Institute, Inc.· Source
Completed
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
NCT03989206· Phase 3· Galderma R&D· Source
Completed
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
NCT03872401· Phase 3· Amgen· Source
Completed
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
NCT03142334· Phase 3· Merck Sharp & Dohme LLC· Source
Report an error